Axsome Q4/FY24 revenue $118.8M/$385.7M; Auvelity growth 124% YoY; Symbravo approved; pipeline NDA submissions on track

Axsome Therapeutics, Inc.

2024-FY EPS reported -$5.99 revenue$385,693,000

Total net product revenue FY24 $385.7M (+88%); Q4 $118.8M (+66% YoY).
Auvelity net sales FY24 $291.4M (+124%); Q4 $92.6M (+89% YoY).
Symbravo approved Jan 30, 2025 for acute migraine; commercial launch in ~4 months.
Patent settlement with Teva extends Auvelity generic entry to 2038–2039; license with pediatric exclusivity.
AXS-05 (Alzheimer's agitation) and AXS-12 (narcolepsy) NDA submissions on track for 2H 2025; AXS-14 NDA submission in 1Q 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.